miR-126&126* Restored Expressions Play a Tumor Suppressor Role by Directly Regulating ADAM9 and MMP7 in Melanoma

@inproceedings{Felli2013miR126126RE,
  title={miR-126&126* Restored Expressions Play a Tumor Suppressor Role by Directly Regulating ADAM9 and MMP7 in Melanoma},
  author={Nadia Felli and Federica Felicetti and Anna Maria Lustri and Maria Cristina Errico and Lisabianca Bottero and Alessio Cannistraci and Alessandra De Feo and Marina Ferreyra Petrini and Francesca Pedini and Mauro Biffoni and Ester Alvino and Massimo Negrini and Manuela Ferracin and Gianfranco Mattia and Alessandra Car{\`e}},
  booktitle={PloS one},
  year={2013}
}
The abnormal expression of several microRNAs has a causal role in tumorigenesis with either antineoplastic or oncogenic functions. Here we demonstrated that miR-126 and miR-126* play a tumor suppressor role in human melanoma through the direct or indirect repression of several key oncogenic molecules. The expression levels of miR-126&126* were elevated in normal melanocytes and primary melanoma cell lines, whereas they markedly declined in metastatic cells. Indeed, the restored expression of… CONTINUE READING

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 38 CITATIONS

MicroRNA Expression Profiling in Psoriatic Arthritis

  • BioMed research international
  • 2018
VIEW 7 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

miR-126 in human cancers: clinical roles and current perspectives.

  • Experimental and molecular pathology
  • 2014
VIEW 8 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

MicroRNA-126-5p downregulates BCAR3 expression to promote cell migration and invasion in endometriosis

Xiannan Meng, Jing Liu, Huimin Wang, Peng Chen, Danbo Wang
  • Molecular and Cellular Endocrinology
  • 2019
VIEW 1 EXCERPT
CITES BACKGROUND

LINC00888 promoted tumorigenicity of melanoma via miR-126/CRK signaling axis

  • OncoTargets and therapy
  • 2018
VIEW 2 EXCERPTS
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 54 REFERENCES

ADAM 17 targets MMP2 and MMP9 via EGFRMEKERK pathway activation to promote prostate cancer cell invasion . 4

LJ Xiao, P Lin, F Lin, X Liu, W Qin
  • Int J Oncol
  • 2012

The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2012
VIEW 1 EXCERPT